Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $110 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a $110 price target.
July 22, 2024 | 3:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Biomarin Pharmaceutical and maintained a $110 price target.
The reiteration of an Overweight rating and a maintained price target of $110 by a reputable analyst can boost investor confidence in Biomarin Pharmaceutical, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100